DAWNZERA Wins CHMP Backing for Preventing Hereditary Angioedema Attacks
Carlsbad, California, 14 November 2025 – Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the Committee for...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Carlsbad, California, 14 November 2025 – Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the Committee for...
ZUG, Switzerland, November 10, 2025 — Pharvaris N.V. (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor...
Scottsdale, AZ — November 6, 2025 : CND Life Sciences (CND) announced the completion of its 50,000th Syn-One Test®,...
Framingham, Massachusetts & Salisbury, England — November 6, 2025 : KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) presented new data at...
September 18, 2025 — Cambridge, Massachusetts Intellia has completed enrollment in the global Phase 3 HAELO trial of lonvoguran...
CARLSBAD, Calif., August 21, 2025 — The U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen), the first...
